Trastuzumab: Dreams, Desperation and Hope

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2024 Mar 16

PMID 38491271

Authors

H Michael Shepard

Affiliations

Soon will be listed here.

Citing Articles

Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumab.

Rudd S, Van Zuylekom J, Cullinane C, Blyth B, Donnelly P Chem Sci. 2025; 16(9):3998-4005.

PMID: 39898305 PMC: 11783091. DOI: 10.1039/d4sc06969b.

References

Sugarman B, Aggarwal B, Hass P, Figari I, Palladino Jr M, Shepard H . Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985; 230(4728):943-5. DOI: 10.1126/science.3933111. View

Urban J, Shepard H, Rothstein J, Sugarman B, Schreiber H . Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci U S A. 1986; 83(14):5233-7. PMC: 323925. DOI: 10.1073/pnas.83.14.5233. View

Lewis G, Aggarwal B, Eessalu T, Sugarman B, Shepard H . Modulation of the growth of transformed cells by human tumor necrosis factor-alpha and interferon-gamma. Cancer Res. 1987; 47(20):5382-5. View

Sugarman B, Lewis G, Eessalu T, Aggarwal B, Shepard H . Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res. 1987; 47(3):780-6. View

Coussens L, Yang-Feng T, Liao Y, Chen E, Gray A, McGrath J . Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985; 230(4730):1132-9. DOI: 10.1126/science.2999974. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Hudziak R, Lewis G, Winget M, Fendly B, Shepard H, Ullrich A . p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989; 9(3):1165-72. PMC: 362707. DOI: 10.1128/mcb.9.3.1165-1172.1989. View

Fendly B, Winget M, Hudziak R, Lipari M, Napier M, Ullrich A . Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 1990; 50(5):1550-8. View

Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M . Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999; 18(13):2241-51. DOI: 10.1038/sj.onc.1202526. View

10.

Stohrer M, Boucher Y, Stangassinger M, Jain R . Oncotic pressure in solid tumors is elevated. Cancer Res. 2000; 60(15):4251-5. View

11.

Carter P, Presta L, Gorman C, Ridgway J, Henner D, Wong W . Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992; 89(10):4285-9. PMC: 49066. DOI: 10.1073/pnas.89.10.4285. View

12.

Baselga J . Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology. 2001; 61 Suppl 2:14-21. DOI: 10.1159/000055397. View